By comprehensively evaluating the serological EGF levels in patients with CRC, we discovered that PDX tumors with low EGF levels exhibited a tumor inhibition value of approximately 40%, whereas those with high EGF levels exhibited a tumor inhibition value of less than 20% with OX40 agonists. Here, EGF is linked to neoplasm.